OSCR
Oscar Health, Inc.
OSCR has the edge over TEVA overall, supported by stronger fundamentals and stronger modeled upside.
TEVA
Teva Pharmaceutical Industries Limited
TEVA's outlook is improving, though it still trails on the overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TEVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
TEVA's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over TEVA in the historical PE scenario, which offers more potential upside but is not a forecast.
TEVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.18 | -86% |
| Forward | 15x | $43.65 | — |
| Fair | 26x | $11.34 | -74% |
| Expensive | 59x | $25.80 | -41% |
| Current | 99x | $43.65 | — |
Historical ranges are pointers, not guarantees.
TEVA's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over TEVA on the outlook, with more favorable revenue expectations.
TEVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TEVA's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
TEVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +542% |
| Q3 2026 | $0.44 | -27% |
| Q2 2026 | $0.61 | +$0.77 |
| Q1 2026 | $1.34 | +$2.49 |
| Q4 2025 | $1.21 | +$2.66 |
| Q3 2025 | $0.60 | +$1.44 |
| Q2 2025 | -$0.16 | +$0.22 |
| Q1 2025 | -$1.15 | -$0.75 |
| Q4 2024 | -$1.45 | -$0.99 |
TEVA has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TEVA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TEVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | -1.9% |
| Q2 2026 | $4.1B | -0.8% |
| Q1 2026 | $4B | +2.3% |
| Q4 2025 | $1.5B | -65% |
| Q3 2025 | $4.5B | +3.4% |
| Q2 2025 | $4.2B | +0.3% |
| Q1 2025 | $3.9B | +1.9% |
| Q4 2024 | $4.2B | -5.1% |
TEVA's revenue is shrinking: $4.4B last quarter, down 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -3.4 points |
| Q2 2026 | -5.6% | -17 points |
| Q1 2026 | 16% | +3 points |
| Q4 2025 | 20% | +21 points |
| Q3 2025 | 20% | +21 points |
| Q2 2025 | 11% | +11 points |
| Q1 2025 | 13% | +19 points |
| Q4 2024 | -0.7% | -17 points |
TEVA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TEVA on cash flow, with more consistent year-over-year improvement.
TEVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121M | -48% |
| Q2 2026 | $307M | +134% |
| Q1 2026 | -$208M | +$24M |
| Q4 2025 | $1B | +128% |
| Q3 2025 | $233M | -57% |
| Q2 2025 | $131M | +2083% |
| Q1 2025 | -$232M | +$16M |
| Q4 2024 | $446M | -58% |
TEVA generated $1.2B in free cash flow over the past year, up 114% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TEVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +18M shares |
| 1 year | +1.6% | +19M shares |
| 3 years | +4.2% | +48M shares |
| 5 years | +6.7% | +74M shares |
| Available history | +8.4% | +92M shares |
TEVA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over TEVA on leverage, with a lower net debt burden relative to earnings.
TEVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.9x | High |
| Q2 2026 | 6.8x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 5.2x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 10.5x | High |
| Q4 2024 | 21.6x | High |
TEVA's net debt is about 6.9 years of its operating earnings (EBITDA), up from 5.2 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TEVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.1 | Overbought |
| Stochastic | 93.7 | Overbought |
TEVA's weekly RSI is 70 (overbought) and its Stochastic is 94 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over TEVA on valuation relative to its sector.
TEVA PE vs Healthcare Sector
| Metric | TEVA | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 26x | 284% above |
| PE % | 100 | 29 | 71 pts above |
TEVA is trading at 99x earnings, a 284% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
TEVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.1 | 6.1% above |
| 20 week MA | $37.6 | 16% above |
| 50 week MA | $34.4 | 27% above |
| 100 week MA | $26.3 | 66% above |
| 200 week MA | $19.4 | 125% above |
TEVA is in an uptrend: it's above all five of its weekly moving averages, and 125% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TEVA on returns for 2026, with the stronger performance.
TEVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.96 | $9.83 | -1.3% |
| 2021 | $9.83 | $8.46 | -14% |
| 2022 | $8.46 | $9.24 | +9.2% |
| 2023 | $9.24 | $10.4 | +13% |
| 2024 | $10.4 | $22.8 | +118% |
| 2025 | $22.8 | $31.9 | +40% |
| 2026 YTD | $31.9 | $43.7 | +37% |
TEVA has finished higher in four of the last six years. It's up 37% so far in 2026.